Wall Street equity research analysts tracking Tenaya Therapeutics project a 12-month median price target sitting at approximately $3.00, with forecasted prediction ranges spanning from a low bound of $2.00 up to higher estimates reaching $5.00 or $8.00 depending on the financial institution. Consensus ratings among covering analysts generally lean toward a strong buy classification, though quantitative factor models suggest balancing these optimistic clinical target expectations against near-term cash burn realities and high volatility.